Top

Gepubliceerd in:

06-07-2023

Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US

Auteurs: Emily M. Rencsok, Natalie Slopen, Karen Autio, Alicia Morgans, Lawrence McSwain, Pedro Barata, Heather H. Cheng, Robert Dreicer, Elisabeth Heath, Rana R. McKay, Mark Pomerantz, Dana Rathkopf, Scott Tagawa, Young E. Whang, Camille Ragin, Folakemi T. Odedina, Daniel J. George, Philip W. Kantoff, Jacob Vinson, Paul Villanti, Sebastien Haneuse, Lorelei A. Mucci, The IRONMAN Registry

Gepubliceerd in: Quality of Life Research | Uitgave 11/2023

Abstract

Purpose

To assess differences in baseline and longitudinal quality of life among Black and White individuals in the US with advanced prostate cancer.

Methods

Secondary analysis of data from the International Registry for Men with Advanced Prostate Cancer (IRONMAN) including US participants newly diagnosed with advanced prostate cancer and identifying their race as Black or White from 2017 to 2023. Participants completed the EORTC QLQ-C30 Quality of Life (QoL) Survey at study enrollment and every 3 months thereafter for up to 1 year of follow-up reporting 15 scale scores ranging from 0 to 100 (higher functioning and lower symptom scores represent better quality of life). Linear mixed effects models with race and month of questionnaire completion were fit for each scale, and model coefficients were used to assess differences in baseline and longitudinal QoL by race.

Results

Eight hundred and seventy-nine participants were included (20% identifying as Black) at 38 US sites. Compared to White participants at baseline, Black participants had worse constipation (mean 6.3 percentage points higher; 95% CI 2.9–9.8), financial insecurity (5.7 (1.4–10.0)), and pain (5.1 (0.9–9.3)). QoL decreased over time similarly by race; most notably, role functioning decreased by 0.7 percentage points (95% CI −0.8, −0.5) per month.

Conclusion

There are notable differences in quality of life at new diagnosis of advanced prostate cancer for Black and White individuals, and quality of life declines similarly in the first year for both groups. Interventions that address specific aspects of quality of life in these patients could meaningfully improve the overall survivorship experience.

vorige artikel Health-related quality of life among people who inject drugs in Australia

volgende artikel Measuring context that matters: validation of the modular Tele-QoL patient-reported outcome and experience measure

Alleen toegankelijk voor geautoriseerde gebruikers

National Cancer Institute: Surveillance, Epidemiology, and End Results Program. (2021). Cancer stat facts: Prostate cancer. Retrieved 3 Apr 2022, from https://seer.cancer.gov/statfacts/html/prost.html

Chornokur, G., Dalton, K., Borysova, M. E., & Kumar, N. B. (2011). Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate, 71(9), 985–997.CrossRefPubMed

Lillard, J. W., Moses, K. A., Mahal, B. A., & George, D. J. (2022). Racial disparities in Black men with prostate cancer: A literature review. Retrieved 15 May 2023, from https://acsjournals.onlinelibrary.wiley.com/doi/https://doi.org/10.1002/cncr.34433

Aggarwal, R. R., Feng, F. Y., & Small, E. J. (2017). Emerging categories of disease in advanced prostate cancer and their therapeutic implications. Cancer Network. Retrieved 5 May 2022, from https://www.cancernetwork.com/view/emerging-categories-disease-advanced-prostate-cancer-and-their-therapeutic-implications

Basch, E., Deal, A. M., Dueck, A. C., Scher, H. I., Kris, M. G., Hudis, C., & Schrag, D. (2017). Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA, 318(2), 197–198.CrossRefPubMedPubMedCentral

Husson, O., de Rooij, B. H., Kieffer, J., Oerlemans, S., Mols, F., Aaronson, N. K., van der Graaf, W. T. A., & van de Poll-Franse, L. V. (2020). The EORTC QLQ-C30 summary score as prognostic factor for survival of patients with cancer in the “real-world”: Results from the population-based PROFILES registry. The Oncologist, 25(4), e722.CrossRefPubMed

Lubeck, D. P., Kim, H., Grossfeld, G., Ray, P., Penson, D. F., Flanders, S. C., & Carroll, P. R. (2001). Health related quality of life differences between black and white men with prostate cancer: Data from the cancer of the prostate strategic urologic research endeavor. The Journal of Urology. https://doi.org/10.1097/00005392-200112000-00057CrossRefPubMed

Eton, D. T., Lepore, S. J., Helgeson, V. S., Schulz, R., Hrebinko, R., Cohen, J., Hakala, R., Salup, R., Bonci, L., Trump, D., Lutins, J., Brufsky, A., Franz, J., Camp-anella, S., Long, S., Schwartz, R., Miller, R., & Benoit, R. (2001). Early quality of life in patients with localized prostate carcinoma an examination of treatment-related, demographic and psychosocial factors. Cancer, 92, 1451–1459.CrossRefPubMed

Rice, K., Hudak, J., Peay, K., Elsamanoudi, S., Travis, J., Lockhart, R., Cullen, J., Black, L., Houge, S., & Brassell, S. (2010). Comprehensive quality-of-life outcomes in the setting of a multidisciplinary, equal access prostate cancer clinic. Urology, 76(5), 1231–1238.CrossRefPubMed

10.

Chhatre, S., Wein, A. J., Malkowicz, S. B., & Jayadevappa, R. (2011). Racial differences in well-being and cancer concerns in prostate cancer patients. Journal of Cancer Survivorship., 5(2), 182–190.CrossRefPubMed

11.

Cella, D., Ivanescu, C., Holmstrom, S., Bui, C. N., Spalding, J., & Fizazi, K. (2015). Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: Additional analyses from the AFFIRM randomized clinical trial. Annals of Oncology., 26(1), 179–185.CrossRefPubMed

12.

Saad, F., Cella, D., Basch, E., Hadaschik, B. A., Mainwaring, P. N., Oudard, S., Graff, J. N., Mcquarrie, K., Li, S., Hudgens, S., Lawson, J., Lopez-Gitlitz, A., Yu, M. K., Smith, M. R., & Small, E. J. (2018). Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. The Lancet Oncology, 19, 1404–1420.CrossRefPubMed

13.

Agarwal, N., Mcquarrie, K., Bjartell, A., Chowdhury, S., Pereira, A. J., Gomes, S., Chung, H., Ozguroglu, M., Soto, A. J., Merseburger, A. S., Uemura, H., Ye, D., Given, R., Cella, D., Basch, E., Miladinovic, B., Dearden, L., Deprince, K., Naini, V., … Chi, K. N. (2019). Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): A randomised, placebo-controlled, phase 3 study. The Lancet Oncology, 20, 1518–1530.CrossRefPubMed

14.

Feyerabend, S., Saad, F., Li, T., Ito, T., Diels, J., Van Sanden, S., De Porre, P., Roiz, J., Abogunrin, S., Koufopoulou, M., & Fizazi, K. L. (2018). Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis. European Journal of Cancer, 103, 78–87.CrossRefPubMed

15.

Sullivan, P. W., Mulani, P. M., Fishman, M., & Sleep, D. (2007). Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Quality of Life Research, 16(4), 571–575.CrossRefPubMed

16.

Zajdlewicz, L., Hyde, M. K., Lepore, S. J., Gardiner, R. A., & Chambers, S. K. (2017). Health-related quality of life after the diagnosis of locally advanced or advanced prostate cancer: A longitudinal study. Cancer Nursing, 40(5), 412–419.CrossRefPubMed

17.

Mucci, L. A., Vinson, J., Gold, T., Gerke, T., Filipenko, J., Green, R. M., Anderson, S. G., Badal, S., Bjartell, A., Chi, K. N., Davis, I. D., Enting, D., Fay, A. P., Lazarus, J., Mateo, J., McDermott, R., Odedina, F. T., Olmos, D., Omlin, A., & George, D. J. (2022). IRONMAN: A novel international registry of men with advanced prostate cancer. JCO Global Oncology. https://doi.org/10.1200/GO.22.00154CrossRefPubMedPubMedCentral

18.

European Organization for Research and Treatment of Cancer. EORTC QLQ-C30 Specimen. Retrieved 9 Oct 2022, from https://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-QLQ-C30-English.pdf

19.

Shih, C. L., Chen, C. H., Sheu, C. F., Lang, H. C., & Hsieh, C. L. (2013). Validating and improving the reliability of the EORTC QLQ-C30 using a multidimensional Rasch model. Value in Health, 16(5), 848–854.CrossRefPubMed

20.

Ford, M. E., Havstad, S. L., & Kart, C. S (2001). Assessing the reliability of the EORTC QLQ-C30 in a sample of older African American and Caucasian adults. Qual Life Res, 10(6), 533–541.

21.

Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (2016). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16(1), 139–144. https://doi.org/10.1200/JCO1998161139CrossRef

22.

Gamper, E. M., Musoro, J. Z., Coens, C., Stelmes, J. J., Falato, C., Groenvold, M., Velikova, G., Cocks, K., Flechtner, H. H., King, M. I. T., & Bottomley, A. (2021). Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials. BMC Cancer, 21(1), 1083.CrossRefPubMedPubMedCentral

23.

EORTC Data Center. (2001). EORTC QLQ-C30 scoring manual, 3rd edn.

24.

Azur, M. J., Stuart, E. A., Frangakis, C., & Leaf, P. J. (2011). Multiple imputation by chained equations: What is it and how does it work? International Journal of Methods in Psychiatric Research, 20(1), 40–49.CrossRefPubMedPubMedCentral

25.

Kaufman, J. S., & Cooper, R. S. (2001). Commentary: Considerations for use of racial/ethnic classification in etiologic research. American Journal of Epidemiology, 154(4), 291–298.CrossRefPubMed

26.

Little, R. J., & Rubin, D. B. (2014). Statistical analysis with missing data (2nd ed.). John Wiley & Sons.

27.

EORTC Quality of Life Group. (2008). EORTC QLQ-C30 reference values. Retrieved 22 Jan 2023, from https://www.eortc.org/app/uploads/sites/2/2018/02/reference_values_manual2008.pdf

28.

Jayadevappa, R., Johnson, J. C., Chhatre, S., Wein, A. J., & Malkowicz, S. B. (2007). Ethnic variation in return to baseline values of patient-reported outcomes in older prostate cancer patients. Cancer, 109(11), 2229–2238.CrossRefPubMed

29.

Litwin, M. S., Mcguigan, K. A., Shpall, A. I., & Dhanani, N. (1999). Recovery of health related quality of life in the year after radical prostatectomy: Early experience. Journal of Urology., 161, 515–519.CrossRefPubMed

30.

Johnson, T. K., Gilliland, F. D., Hoffman, R. M., Deapen, D., Penson, D. F., Stanford, J. L., Albertsen, P. C., & Hamilton, A. S. (2004). Racial/ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. Journal of Clinical Oncology, 22(20), 4193–4201.CrossRefPubMed

31.

Halbert, C. H., Coyne, J., Weathers, B., Mahler, B., Delmoor, E., Vaughn, D., Malkowicz, S. B., Lee, D., & Troxel, A. (2010). Racial differences in quality of life following prostate cancer diagnosis. Urology, 76(3), 559–564.CrossRefPubMed

32.

Ravi, P., Karakiewicz, P. I., Roghmann, F., Gandaglia, G., Choueiri, T. K., Menon, M., McKay, R. R., Nguyen, P. L., Sammon, J. D., Sukumar, S., Varda, B., Chang, S. L., Kibel, A. S., Sun, M., & Trinh, Q. D. (2014). Mental health outcomes in elderly men with prostate cancer. Urologic Oncology: Seminars and Original Investigations, 32(8), 1333–1340.CrossRefPubMed

33.

Erim, D. O., Bensen, J. T., Mohler, J. L., Fontham, E. T. H., Song, L., Farnan, L., Delacroix, S. E., Peters, E. S., Erim, T. N., Chen, R. C., & Gaynes, B. N. (2019). Patterns and predictors of self-reported clinical diagnosis and treatment for depression in prostate cancer survivors. Cancer Medicine, 8(8), 3648–3658.CrossRefPubMedPubMedCentral

34.

Eylem, O., Eylem, O., De Wit, L., Van Straten, A., Steubl, L., Melissourgaki, Z., Danlsman, G. T., De Vries, R., Kerkhof, A. J. F. M., Bhui, K., & Cuijpers, P. (2020). Stigma for common mental disorders in racial minorities and majorities a systematic review and meta-analysis. BMC Public Health, 20(1), 1–20. https://doi.org/10.1186/s12889-020-08964-3CrossRef

35.

Dickey, S. L., & Ogunsanya, M. E. (2018). Quality of life among black prostate cancer survivors: An integrative review. American Journal of Men’s Health, 12(5), 1648.CrossRefPubMedPubMedCentral

36.

Chatters, L. M., Taylor, R. J., Bullard, K. M., & Jackson, J. S (2009). Race and ethnic differences in religious involvement: African Americans, Caribbean Blacks and non-Hispanic Whites. Ethn Racial Stud, 32(7), 1143–1163.

37.

Beebe-Dimmer, J. L., Ruterbusch, J. J., Cooney, K. A., Bolton, A., Schwartz, K., Schwartz, A. G., & Heath, E. (2019). Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-medicare investigation. Cancer Medicine, 8(6), 3325.CrossRefPubMedPubMedCentral

38.

Khalaf, D. J., Sunderland, K., Eigl, B. J., Kollmannsberger, C. K., Ivanov, N., Finch, D. L., Oja, C., Vergidis, J., Zulfiqar, M., Gleave, M. E., & Chi, K. N. (2019). Health-related quality of life for abiraterone plus prednisone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: Results from a phase II randomized trial. European Urology, 2019(75), 940–947. https://doi.org/10.1016/j.eururo.2018.12.015CrossRef

39.

Stenzl, A., Dunshee, C., De Giorgi, U., Alekseev, B., Iguchi, T., Szmulewitz, R. Z., Flaig, T. W., Tombal, B., Morlock, R., Ivanescu, C., Ramawamy, K., Saad, F., & Armstrong, A. J. (2020). Effect of enzalutamide plus androgen deprivation therapy on health-related quality of life in patients with metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES randomised, placebo-controlled, phase 3 study. European Urology, 78(4), 603–614.CrossRefPubMed

40.

Boevé, L., Hulshof, M. C. C. M., Verhagen, P. C. M. S., Twisk, J. W. R., Witjes, W. P. J., de Vries, P., van Moorselaar, R. J. A., van Andel, G., & Vis, A. N. (2021). Patient-reported quality of life in patients with primary metastatic prostate cancer treated with androgen deprivation therapy with and without concurrent radiation therapy to the prostate in a prospective randomised clinical trial; data from the HORRAD trial. European Urology, 79(2), 188–197.CrossRefPubMed

41.

Rush, H. L., Murphy, L., Morgans, A. K., Clarke, N. W., Cook, A. D., Attard, G., Macnair, A., Dearnaley, D. P., Parker, C. C., Russell, J. M., Gillessen, S., Matheson, D., Millman, R., Brawley, C. D., Pugh, C., Tanguay, J. S., Jones, R. J., Wagstaff, J., Rudman, S., & Langley, R. E. (2022). Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial. Journal of Clinical Oncology, 40(8), 825–836.CrossRefPubMed

42.

Drevinskaite, M., Dadoniene, J., Miltiniene, D., Patasius, A., & Smailyte, G. (2022). Clinical medicine association between androgen deprivation therapy and the risk of inflammatory rheumatic diseases in men with prostate cancer: Nationwide cohort study in Lithuania. Journal of Clinical Medicine. https://doi.org/10.3390/jcm11072039CrossRefPubMedPubMedCentral

43.

Zobniw, C. M., Causebrook, A., & Fong, M. K. (2014). Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Research and Reports in Urology. https://doi.org/10.2147/RRU.S29003CrossRefPubMedPubMedCentral

44.

Richardson, L. D., & Norris, M. (2010). Access to health and health care: How race and ethnicity matter. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 77(2), 166–177.CrossRef

45.

Morgans, A. K., Van Bommel, A. C. M., Stowell, C., Abrahm, J. L., Basch, E., Bekelman, J. E., Berry, D. L., Bossi, A., Davis, I. D., de Reijke, T. M., Denis, L. J., Evans, S. M., Fleshner, N. E., George, D. J., Kiefert, J., Lin, D. W., Matthew, A. G., McDermott, R., Payne, H., & Penson, D. F. (2015). Development of a standardized set of patient-centered outcomes for advanced prostate cancer: An international effort for a unified approach. European Urology, 68(5), 891–898.CrossRefPubMed

46.

Ford, M. E., Havstad, S. L., & Kart, C. S. (2001). Assessing the reliability of the EORTC QLQ-C30 in a sample of older African American and Caucasian adults. Quality of Life Research., 10, 533–541.CrossRefPubMed

Titel: Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US
Auteurs: Emily M. Rencsok
Natalie Slopen
Karen Autio
Alicia Morgans
Lawrence McSwain
Pedro Barata
Heather H. Cheng
Robert Dreicer
Elisabeth Heath
Rana R. McKay
Mark Pomerantz
Dana Rathkopf
Scott Tagawa
Young E. Whang
Camille Ragin
Folakemi T. Odedina
Daniel J. George
Philip W. Kantoff
Jacob Vinson
Paul Villanti
Sebastien Haneuse
Lorelei A. Mucci
The IRONMAN Registry
Publicatiedatum: 06-07-2023
Uitgeverij: Springer International Publishing
Gepubliceerd in: Quality of Life Research / Uitgave 11/2023
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-023-03468-0

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Purpose

Methods

Results

Conclusion

Log in om toegang te krijgen

Andere artikelen Uitgave 11/2023

Response shift in parent-reported psychopathology in children with chronic physical illness

Effects ﻿of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II)

Health related quality of life in adults after late repair of tetralogy of fallot: experience from a low-middle income country

Social factors of health-related quality of life in older adults: a multivariable analysis

Effects of an autonomy-supportive intervention programme (ASIP) on self-care, quality of life, and mental health in heart failure patients: a randomized controlled trial

Development and validation of the while-in-bed-smartphone-use-induced sleep procrastination scale (WSPS) in Chinese undergraduates with/without problematic smartphone use

Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II)